- Home
- NMM vs NRIX Comparison
NMM vs NRIX Comparison
Compare NMM & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMM
- NRIX
- Stock Information
- Founded
- NMM 2007
- NRIX 2009
- Country
- NMM Monaco
- NRIX United States
- Employees
- NMM N/A
- NRIX N/A
- Industry
- NMM Marine Transportation
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- NMM Consumer Discretionary
- NRIX Health Care
- Exchange
- NMM Nasdaq
- NRIX Nasdaq
- Market Cap
- NMM N/A
- NRIX 1.3B
- IPO Year
- NMM 2007
- NRIX 2020
- Fundamental
- Price
- NMM $64.10
- NRIX $21.67
- Analyst Decision
- NMM Strong Buy
- NRIX Strong Buy
- Analyst Count
- NMM 1
- NRIX 13
- Target Price
- NMM $80.00
- NRIX $26.92
- AVG Volume (30 Days)
- NMM 274.7K
- NRIX 597.3K
- Earning Date
- NMM 10-31-2024
- NRIX 10-10-2024
- Dividend Yield
- NMM 0.31%
- NRIX N/A
- EPS Growth
- NMM N/A
- NRIX N/A
- EPS
- NMM 12.93
- NRIX N/A
- Revenue
- NMM $1,311,139,000.00
- NRIX $62,303,000.00
- Revenue This Year
- NMM $6.90
- NRIX N/A
- Revenue Next Year
- NMM $9.88
- NRIX $9.92
- P/E Ratio
- NMM $4.93
- NRIX N/A
- Revenue Growth
- NMM N/A
- NRIX 2.25
- 52 Week Low
- NMM $21.18
- NRIX $4.22
- 52 Week High
- NMM $65.89
- NRIX $26.31
- Technical
- Relative Strength Index (RSI)
- NMM 73.24
- NRIX 36.60
- Support Level
- NMM $61.40
- NRIX $22.90
- Resistance Level
- NMM $65.89
- NRIX $24.00
- Average True Range (ATR)
- NMM 1.98
- NRIX 1.26
- MACD
- NMM 0.36
- NRIX -0.41
- Stochastic Oscillator
- NMM 84.27
- NRIX 8.48
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.